Use of 4-(1-carboxy-ethylcarbamoyl)-4-(5-[1,2]dithiolan-3-yl-pentanoylamino)-butyric acid derivatives in the manufacture of medicaments

摘要

The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula I: and methods of using such compounds to activate cytoprotective kinases. The values and preferred values of the variables in Structural Formula I are defined herein.